Antibodies to SARS-CoV-2 and risk of future sickness

  1. Joakim Dillner
  2. K. Miriam Elfström
  3. Jonas Blomqvist
  4. Carina Eklund
  5. Camilla Lagheden
  6. Sara Nordqvist-Kleppe
  7. Cecilia Hellström
  8. Jennie Olofsson
  9. Eni Andersson
  10. August Jernbom Falk
  11. Sofia Bergström
  12. Emilie Hultin
  13. Elisa Pin
  14. Anna Månberg
  15. Peter Nilsson
  16. My Hedhammar
  17. Sophia Hober
  18. Johan Mattsson
  19. Laila Sara Arroyo Mühr
  20. Kalle Conneryd Lundgren
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Background

The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown.

Method

We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">https:ClinicalTrials.gov</ext-link> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04411576">NCT04411576</ext-link> ).

Results

Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)).

Conclusion

Presence of viral antibodies marks past disease and protection against excess risk of future disease.

Related articles

Related articles are currently not available for this article.